Putnam, CT – (June 1, 2022) – Foster/MedNet will represent Arkema in all countries in Europe, Middle East and Africa beginning July 1, 2022. This agreement includes Arkema’s Pebax® MED, Rilsan® MED, Rilsamid® MED, Rilsan® Clear MED and Kynar® MED product ranges.
MedNet, headquartered in Germany, has been supplying the medical industry since 1990. As a supplier of raw materials and components, they have developed outstanding knowledge and expertise which are essential to successfully grow this highly technical market.
Foster Corporation, Arkema’s primary High Performance Medical Polymers distributor globally and historical partner, will support MedNet by supplying them with their extensive range of compounds based on Arkema’s specialty polyamides and will bring their in-depth technical knowledge of Arkema’s high performance polymers portfolio.
“We are extremely pleased to establish this relationship with MedNet and Foster,” said Francois Ruas, Health and Beauty Global Market Manager at Arkema. “This distribution partnership expands our reach and expertise in the medical market and will help to grow our business in EMEA, with our advanced bio-circular (ABC) Rilsan® MED polyamide 11 and our flagship Pebax® MED elastomers.”
“Building on our steady and successful collaboration with Foster Corporation for many years, we look forward to deepening relationships and expanding sales activities for medical resins by partnering with Arkema,” said Matthias Heinz, Managing Director at MedNet. “Based on our critical market knowledge and experience, as well as our long-standing customer relations, we are well positioned to support the success of all parties involved and provide the best possible service to our customers.”
“Foster and Arkema have had a long and successful relationship regards the marketing and distribution of Arkema’s medical grade products into critical medical applications in North America and Asia” said Larry Johnson, President, Foster Distribution. “Now, the reach of this partnership will extend to EMEA thanks to the incorporation of our long-standing partner MedNet, whose experience in the healthcare market is unmatched. MedNet will be able to leverage that experience, with Foster’ expertise to further develop new business opportunities for Arkema healthcare products in this region. We can assure customers for Arkema’s high performance polymers medical products in the EMEA that the Foster/MedNet partnership will work together diligently to ensure an efficient transition and provide unmatched customer service.”
During this transition period, please contact Matthias Heinz, Managing Director at MedNet. [email protected] +49 251 32266-0
About Foster Corporation
For over thirty years Foster Corporation has been serving medical device manufacturers with industry leading technology and service in biomedical materials. These include custom medical compounds, implantable materials, and polymer distribution. Within ISO 13485:2016 facilities, Foster offers comprehensive support to customers from formulation development through production.
About Mednet
MedNet was founded in 1990 and is a supplier of medical components for interventional procedures and other medical device applications. Through our network of leading manufacturers, we offer component and materials engineering to the medical device and pharmaceutical industries.
About Arkema
Building on its unique set of expertise in materials science, Arkema offers a portfolio of first-class technologies to address ever-growing demand for new and sustainable materials. With the ambition to become in 2024 a pure player in Specialty Materials, the Group is structured into 3 complementary, resilient and highly innovative segments dedicated to Specialty Materials -Adhesive Solutions, Advanced Materials, and Coating Solutions- accounting for some 85.5% of Group sales in 2021, and a well-positioned and competitive Intermediates segment. Arkema offers cutting-edge technological solutions to meet the challenges of, among other things, new energies, access to water, recycling, urbanization and mobility, and fosters a permanent dialogue with all its stakeholders. The Group reported sales of around €9.5 billion in 2021, and operates in some 55 countries with 20,200 employees worldwide.